Published on March 14, 2014
Sherif El Refai
As big as the subject of Pharmacogenomics is these days, there is still one major hurdle it has yet to surpass – will the burden of cost and time ever be less than the potential benefits achieved from full scale genotyping of patients? The Pharmacogenomic Quandary
Of all the universities studying this topic, Vanderbilt has implemented a full scale service, the PREDICT program, that genotypes any patient with a history of coronary artery stent or has a >40% chance of receiving clopidogrel, warfarin or a statin in the next three years. Vanderbilt PREDICT Vanderbilt University Practice
Sherif El Refai is currently researching pharmacogenomics & individualized therapy at the UNC Eshelman School of Pharmacy. UNC CPIT Conclusion
Primary Outcome Measures: Feasibility of PreEmptive Genotyping Testing [ Time Frame: From initial clinic visit to post-operative discharge, expected ...
Preemptive Genotyping for Personalized Medicine: DesignoftheRightDrug,RightDose,RightTimedUsing Genomic Data to Individualize Treatment Protocol
For preemptive genotyping to be widely deployed, the structure of electronic health records (EHRs) will need to evolve so that they enable the retrieval, ...
Posts about preemptive genotyping (PG). written by tanyaznamenskaya